[Endogenous persistent hypoglicemia of adult: case report].
Persistent Hyperinsulinemic Endogenous hypoglycemia in adults is, in most cases, due to Insulinoma. Nesidioblastosis, a peculiar functional hyperinsulinemia from hypertrophic beta cells, has been described mainly in newborns. This article describes a 34-year-old patient who presented hyperinsulinemic endogenous hypoglycemia clinical and laboratorial situation (Fasting glycemia: 54 mg/dl / Reference Interval (RI): 60-99 mg/dl; Serum insulin: 70.9 mcU/ml / RI: < 29.1 mcU/ml; e C peptide: 7.1 ng/ml / RI: 1.1-5.0 ng/ml). It was suspected Insulinoma. Because of the lack of typical images in radiologic exams (ultrasonography and computerized tomography) it had been decided to do laparotomy, but it was not found any macroscopic pancreatic tumor. Histological and histochemistry examination of a distal pancreatic segment showed alteration suitable to nesidioblastosis. The patient presented clinical stability during the next two months, however, after that, there was a recurrence of a hypoglycemia crisis, refractory to Octreotide administration. It was done "octreoscan", which showed expanded nesidioblastosis, being done extensive partial pancreatectomy. Octreotide was used again, with a good control of the hypoglycemia crisis. As it is an uncommon diagnosis in an adult, the objective of this article is to describe the diagnostic and therapeutic aspects in cases of hyperinsulinemic endogenous hypoglicemia.
Costa
Raquel R
RR
Departamento de Fisiologia e Clínica e Endocrinologia e Metabologia, Hospital Universitário São José, Faculdade de Ciências Médicas de Minas Gerais, Belo Horizonte. raquelrangel@ig.com.br
Maia
Frederico F R
FF
Araújo
Levimar R
LR
D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001786:Blood Glucose; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D007003:Hypoglycemia / Q000209:etiology* / Q000628:therapy; D007340:Insulinoma / Q000175:diagnosis; D046768:Nesidioblastosis / Q000150:complications* / Q000175:diagnosis / Q000628:therapy; D015282:Octreotide / Q000627:therapeutic use; D010180:Pancreatectomy; D010190:Pancreatic Neoplasms / Q000175:diagnosis / Q000473:pathology
D018931:Antineoplastic Agents, Hormonal; D001786:Blood Glucose; D015282:Octreotide